Thousands of cancer patients from minority ethnic backgrounds in England will now have access to expanded NHS genetic testing for minority ethnic cancer patients, a move designed to correct a systemic gap in chemotherapy safety that has historically disadvantaged non-white patients.
The routine genetic screening, conducted before the administration of chemotherapy, is intended to identify patients at high risk for severe, and sometimes fatal, adverse reactions. By expanding the scope of the test to include a fifth genomic variant more common in Black and minority ethnic populations, clinicians can now personalize drug dosages to ensure safer treatment outcomes.
For years, the standard safety net for chemotherapy was built on a narrow genetic foundation. Until recently, the NHS tested for only four types of DPYD gene variants—markers predominantly found in people of white European descent. This meant that patients of African or Asian ancestry could be falsely cleared for a standard dose of chemotherapy, unaware that they carried a different genetic variant that made the treatment toxic to their systems.
The stakes are particularly high for those receiving fluoropyrimidine-based chemotherapy, a common treatment used for various cancers. It is estimated that up to 40% of the 38,000 patients treated with these drugs in England may experience an adverse reaction, ranging from nausea and mouth sores to life-threatening toxicity.
Closing the gap in precision medicine
The DPYD gene provides instructions for making an enzyme that breaks down fluoropyrimidine drugs. When a patient has a variant of this gene that reduces enzyme activity, the chemotherapy builds up in the body, leading to severe side effects. Because medical research has historically relied on white European cohorts, the “safety net” of genetic testing was not designed to catch everyone equally.
Dr. Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, describes the introduction of the fifth variant test as a shift from rhetoric to clinical action. “Patients of African ancestry deserve the same standard of safety as everyone else, and now clinicians have the means to deliver it,” L’Esperance said. She noted that this is the first concrete response to evidence that Black and ethnic minority patients were being failed by tests designed around white European genetics.
The rollout is already producing tangible results. Since the expanded testing went live at the Manchester University NHS Foundation Trust last September, three patients from minority ethnic backgrounds have already had their starting chemotherapy doses altered based on the results, directly reducing their risk of a potentially fatal reaction.
A broader pattern of health inequality
This genetic discrepancy is part of a wider pattern of disparities in cancer care for Black and Asian patients in the UK. Data indicates that ethnic minority patients often face a more arduous path to recovery, including longer wait times for an initial cancer diagnosis and a higher number of GP visits before the disease is identified.
Beyond diagnosis, there are systemic gaps in the patient experience. Many Black cancer patients report feeling less supported by hospital staff during their treatment compared to their white counterparts. This combination of delayed diagnosis and suboptimal supportive care contributes to poorer overall health outcomes.
Prof. Habib Naqvi, chief executive of the NHS Race and Health Observatory, emphasized that while genomics and precision medicine offer a path toward more targeted and effective care, the underlying data must be inclusive. Naqvi warned that ethnic minority groups remain under-represented in medical research and genomic biobanks, arguing that medical advances can only benefit everyone if research is conducted across diverse populations.
The path toward tailored oncology
The expansion of the DPYD test is being led by the North West NHS Genomic Medicine Service as part of a broader commitment to reducing race-based health inequalities. By identifying the fifth variant, the NHS is moving toward a model of “personalized” chemotherapy, where the drug is tailored to the patient rather than the patient being forced to fit a standardized, European-centric protocol.
Prof. Dame Sue Hill, chief scientific officer for NHS England and senior responsible officer for NHS Genomics, described the discovery and implementation of the fifth variant as “fantastic news” that allows for more tailored care. She noted that the service has already demonstrated how this can improve treatment for patients of African ancestry, ensuring that no patient is disadvantaged by a lack of access to appropriate screening.
Summary of DPYD Testing Evolution
| Feature | Previous Standard | New Expanded Standard |
|---|---|---|
| Variants Tested | Four (4) | Five (5) |
| Genetic Focus | White European backgrounds | Inclusive of Black and minority ethnic backgrounds |
| Clinical Goal | Avoid toxicity in European cohorts | Equity in safety for all ethnic ancestries |
| Primary Impact | Higher risk of toxicity for non-white patients | Personalized dosing based on broader genomic data |
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their oncology team regarding genetic testing and chemotherapy dosing.
The next phase of this initiative involves the further integration of diverse genomic data into standard clinical practice across all NHS trusts in England. Official updates on the expansion of the genomic medicine service are expected as part of the ongoing NHS commitment to reducing health inequalities.
We invite readers to share their experiences with precision medicine or comment on the importance of diversity in medical research in the section below.
